Zimmer Biomet

Company Overview

Zimmer Biomet Holdings, Inc. (NYSE: ZBH), headquartered in Warsaw, Indiana, USA, was established in 1927 and renamed Zimmer Biomet in June 2015. It is a global leader in medical technology, specializing in orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, craniomaxillofacial & thoracic products, dental implants, and related surgical products. The company operates in over 25 countries and sells products in more than 100 countries, employing approximately 17,000 staff under CEO Ivan Tornos. It has been recognized by Forbes, Newsweek, and VIQTORY for its workplace excellence and corporate responsibility.

Core Business and Products

Zimmer Biomet offers a broad portfolio of musculoskeletal healthcare products, including:

• ROSA® Robotics: Advanced robotic solutions for knee care to enhance surgical precision.

• Persona® Revision Knee: Knee revision system improving joint stability and long-term implant performance.

• ViVi® Surgical Helmet System: Surgical helmet improving air quality, comfort, and visibility.

• Signature™ ONE: 3D digital surgical planning system supporting personalized procedures.

• A.L.P.S.® Clavicle Plating System: Clavicle fixation addressing compatibility challenges of traditional plates.

• NCB Periprosthetic Fracture Plate System: System for fracture repair post-joint replacement emphasizing reliability and ease of use.

Market Position and Key Products

Zimmer Biomet is a global leader in musculoskeletal healthcare solutions, serving orthopedic surgeons, neurosurgeons, hospitals, distributors, and healthcare organizations. Its products treat patients with bone, joint, or soft tissue disorders or injuries. In 2025, Q2 revenue reached $2.077 billion (7% YoY growth), with net profit of $153 million (37% YoY decrease). Cumulative H1 revenue was $3.986 billion (+4.05% YoY) and net profit was $336 million (-19.21% YoY).

Financial Performance

As of September 30, 2025, Zimmer Biomet's operating margin was 19.76%, return on assets 4.36%, and return on equity 6.53%. Revenue per share was $39.25 (+4.11% YoY), EBITDA growth was 2.39%, and diluted EPS growth was -14.33%.

Recent Developments

In July 2025, Zimmer Biomet announced plans to acquire Monogram Technologies, Inc., enhancing its robotic and navigation solutions portfolio. Monogram’s mBôs system offers semi-autonomous and fully autonomous robotic solutions for total knee arthroplasty, with FDA clearance for the semi-autonomous robot in March 2025 and full autonomy expected in late 2027/early 2028. In September 2025, Zimmer Biomet sued Deloitte for misrepresentation in delivering an ERP system, seeking over $172 million in damages.

Awards and Honors

Zimmer Biomet has been recognized on Forbes' Best-in-State Employers in Indiana (2020, 2021), Newsweek’s America’s Most Responsible Companies (2021), and VIQTORY’s Military Friendly Employer (2019, 2020). Additional accolades include the Indiana Manufacturers Association Manufacturing Excellence Award (2020) and ComputerWorld’s Best Places to Work in IT (2018–2020).

Legal Disputes

In 2025, Zimmer Biomet faced lawsuits regarding its Comprehensive Reverse Shoulder System, with allegations that the company marketed devices despite known potential malfunctions, causing harm to patients.

Contact Information

Headquarters: Warsaw, Indiana, USA